

A family of four is running away from the camera through a field of tall, golden grass. The sun is low on the horizon, creating a warm, golden glow. The father is on the left, wearing a red and black plaid shirt over a white t-shirt and brown pants, with his arms outstretched. The mother is on the right, wearing a striped shirt and a red plaid skirt, also with her arms outstretched. Two children are in the middle; one is wearing a striped shirt and a hat, and the other is wearing a red and black plaid shirt. They are all running towards the horizon.

Brighter

We are human
innovation.

Q3

Interim Report

July — September 2021

Contents.

Human innovation.	3
CEO Statement – A new Brighter chapter.	4
Why invest in Brighter?	5
Significant events during the quarter.	6
Financial Summary.	7
Comments on the financial results.	8
Sales.	10
Business risks and other information.	11
Financial Statements.	12
Notes.	18
Significant events after the end of the quarter.	23
Submission of interim report.	24
About Brighter.	25



4.

CEO statement.

At the beginning of this quarter, Erik Lissner joined Brighter as interim CEO.

7.

Financial Summary.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020	Jan-Dec 2019
Net income	1,449	2,470	5,234	6,310	12,286	2,398
Operating result (including associated company result)	-46,829	-40,977	-147,987	-125,386	-230,577	-79,809
Net financial items	-833	4,345	-25,793	-2,584	-13,575	-9,875
Result before tax	-47,662	-36,632	-173,780	-127,970	-244,152	-89,685
Total assets	303,660	384,047	303,660	384,047	338,917	255,664
Equity per share (SEK)	0.63	0.84	0.63	0.84	0.84	0.63

10.

Sales.

During this quarter, several important commercial milestones were reached for both Actiste® and for our subsidiaries Camanio and Nectarine Health™.



Human innovation.

On a mission to improve the lives of millions of people.



A human innovation company.

Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, we aim to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Currently the group has offices in Stockholm, Dubai, Jakarta and New York.

The Brighter Innovation Group.

This is Brighter – on a mission to improve health for everyone, everywhere.



Brighter.

Diabetes Management as a Service. Proactive and data-driven healthcare in Diabetes.

Read more [here](#).

Fully owned/founded by Brighter.



Nectarine Health.

IoT and Deep Learning to assist senior living and independent living facilities.

Read more [here](#).

Fully owned subsidiary.



Camanio.

Enabling a smooth transition to digital care at home.

Read more [here](#).

Fully owned subsidiary.



Accumbo.

Sweden's first digital healthcare service specially adapted for patients with high blood pressure.

Read more [here](#).

Minority stake investment.

A new Brighter chapter.

The third quarter of the year was characterized by several important commercial milestones carrying Brighter forward. Brighter's Actiste® received final outstanding approval in Qatar and the Company is now focused on the upcoming product launch. We are in ongoing discussions with distributors in the African market regarding the Actiste® service, and are continuously working with existing and new potential partners in the United Arab Emirates. In Indonesia, we are working closely with Padjadjaran University to drive a research project where 100 patients with diabetes will be using Actiste® Mini. After the quarter we also signed a reseller agreement with Medico, the leading provider of cloud-based healthcare-management systems in Indonesia. Medico also offers a telemedicine app for patients, and wants to initially be able to offer Actiste® Mini to its patients. This, together with our collaboration with the university and hospitals is forming a solid foundation for our commercialisation plans in the country.

During the third quarter we received a preliminary assessment from the UAE's Ministry of Health and Prevention that the data storage elements in Brighter's Actiste® Diabetes Management Solution will be exempt from the current data localization requirements in the Health Data Law in the UAE. We have also continued to expand Brighter's sales channels in Sweden by entering into a commercial collaboration agreement with VivBon AB, a Swedish service provider that offers a wide range of personalized services and solutions for seniors and their relatives. With this collaboration we aim to increase our user base and gain valuable insights and data on the user experience.

During the quarter our subsidiary Camanio won allocation decisions for stationary care alarms and alarm monitoring with Vansbro-, Österåker- and Borgholm Municipalities. After the quarter Camanio also won allocation decisions for Ragunda and Strömsund.

Our subsidiary Nectarine Health™ signed agreements with Solutionology Health, CK-Caregivers and Peace of Mind and continued expanding trials in the U.S. The company was also granted two U.S. patents and received approval from Apple and Google to release Nectarine Health™ customer interface app.

In the beginning of November, the Board, subject to the Extra General Meeting on December 7, decided to carry out a rights issue to secure additional capital. This, together with the procured credit facility, will enable us to continue our commercialization efforts and strengthen our position. I think it is a great show of trust that the whole Board of Directors as well as the majority of the Company's leadership, including me, have already chosen to invest in the issue as either underwriters or with subscription commitments. It is important to keep our momentum and move forward to build upon and execute on the commercial preparations we have achieved. The Board is also continuing its ongoing discussions to divest its holdings in Camanio, Nectarine Health™ and Accumbo, in order to focus all our efforts on our core business.

Now, after taking on the role as interim CEO in July 2021, I feel both expectant and positive about the future. I have great faith in the platform we stand on, but also in the ability and competence among all our employees. To improve efficiency, we have made some organizational changes during the



last quarter. Among other things, the number of members in the executive management have been reduced. I believe that with a smaller team we can move faster, iterate at a higher frequency, and be a more innovative company. We are also continuously working on reducing the number of consultants and making sure that we are fit for purpose in all areas of the business.

Our main focus forward will be the continued commercialization of Actiste®, where we have taken the first important steps into the market. We will also continue to develop our digital solutions, and thus try to take a larger place in patients' ecosystems. Through more precise information and proactive treatment, we can not only become more relevant to the patient, but we can also become a more valuable partner in healthcare. Our efforts remain high and we have full focus on 2022 being the year when Brighter reaches the market, partly with Actiste, but also with our digital platform where our goal is to create value for our customers and users through more accurate insights.

Erik Lissner
Interim CEO

Why invest in Brighter?

Brighter is here to improve the lives of millions of people with diabetes around the world. At the same time we offer an innovative technology platform for the healthcare sector which increases the efficiency and lowers the cost. We believe there are five simple and compelling reasons to invest in Brighter.

Our purpose - to improve the lives of millions of people with diabetes while driving innovation in the healthcare sector.

Diabetes is one of the fastest growing health challenges in modern times. Today, more than 463 million people around the world are affected by diabetes, and the numbers are predicted to nearly double by the year 2045. The cost for diabetes care is extensive - \$ 760 billion in 2019. Poor adherence to the medical regimen is a major clinical problem in the management of patients with diabetes, which can lead to unnecessary complications and increased cost for society. With our technology and innovative services in targeted markets, we aim to improve health outcomes and wellbeing amongst people with diabetes and facilitate increased efficiency throughout the healthcare system.

Our IP portfolio - a strong asset in digital and connected healthcare.

Brighter has since the beginning built a strong IP portfolio in digital and connected healthcare.

With today's approximately 70 approved patents globally and approximately 45 ongoing patent applications we consider the IP portfolio, and the commercial licensing opportunities it creates, as its own active business area with significant potential.

The Company has approved patents worldwide, including in Europe, the United States, India, Indonesia, Brazil, Japan, South Korea, China and Mexico.

Our products and solutions - in line with the global trends of digital healthcare.

With the massive growth of people diagnosed with diabetes and the rising cost for society, the need for intuitive, intelligent and connected medical products and services providing insights increase.

Brighter's Actiste® and "The Benefit Loop" already support data-driven and mobile healthcare services that aim to simplify, streamline and improve the information flow of relevant and reliable data.

The ambition forward is to further develop our services in order to increase our offer of insights driven data analytics solutions. We aim to capitalize on an even larger share of Brighter's offering and accelerate our establishment in the market.



Our partners - important stakeholders in key markets.

Besides continuous contacts and projects with key opinion leaders, governments and healthcare providers, Brighter has established partnerships and agreements in all its prioritized markets. Among those are AlDanah Medical Company, one of the leading distributors of medical and biomedical equipment in Qatar, DiapointME, AlZahra hospital and Prime Healthcare in the UAE. In Indonesia - Padjadjaran University and hospitals have decided to drive a research project and we have a reseller agreement with Medico, Indonesia's leading provider of cloud-based healthcare-management systems. We have also established agreements to expand Brighter's sales channels in Sweden.

Our People - experienced management and passionate team.

We have an experienced management team, with a strong track record and employees that are really passionate about tech and digital development, all our functions are driving digital transformation in order to drive the business forward.

Significant events during the quarter.

- Brighter's Actiste® receives final outstanding approval in Qatar.
- Erik Lissner is appointed interim Chief Executive Officer.
- Christopher Robinson is appointed interim Chief Financial Officer.
- Karin O'Connor and Clas Lindbergson are elected as new board members and Christer Trägårdh is elected as Chairman of the Board.
- The previous CEO Henrik Norström and the previous chairman Truls Sjöstedt do not receive discharge of liability for the fiscal year 2020. All other members of the board receive discharge of liability.
- Brighter enters into a commercial collaboration agreement with VivBon AB in Sweden for the Actiste® portfolio.
- Brighter receives clarification from the United Arab Emirates Ministry of Health and Prevention regarding data storage and processing in Actiste® Diabetes Management Solution.
- Brighter carries out a private placement of 39.7 MSEK.
- Brighter Commences legal action against Unwrap Finance Nordic AB.
- Brighter's Subsidiary Nectarine Health™ receives approval to release the Nectarine Health™ customer interface app.
- Brighter's subsidiary Nectarine Health™ is granted two US patents.
- Nectarine Health™ enters into an agreement and expands its friendly user trials with Solutionology Health.
- Nectarine Health™ at Home is registered with the FDA.
- Brighter's subsidiary Camanio wins allocation decisions for stationary care alarms and alarm monitoring with Vansbro Municipality.
- Brighter's subsidiary Camanio wins allocation decisions for stationary care alarms and alarm monitoring with Österåker Municipality.
- Brighter's subsidiary Nectarine Health™ signs an agreement with CK-Caregivers & continues expanding trials in the US
- Brighter is notified that its distributors in Nigeria and Ghana wish to renegotiate the distribution agreements – estimated revenues will either be substantially reduced or not materialize.
- Brighter's subsidiary Nectarine Health™ signs an agreement with Peace of Mind Aging expanding trials in the US.
- Brighter signs a collaboration agreement for Actiste Mini with Padjadjaran University in Indonesia.
- Brighter carries out a Capital Markets Day.
- Brighter's subsidiary Camanio wins allocation decisions for stationary care alarms and alarm monitoring with Borgholm Municipality.
- Founder files claim against Brighter AB over alleged share lending agreement.



Financial Summary.

July – September 2021.

- Net sales amounted to TSEK 1,449 (2,470).
- Operating result amounted to TSEK -46,829 (-40,977).
- Earnings before tax amounted to TSEK -47,662 (-36,632).
- Operating cash flow amounted to TSEK -55,595 (-35,361)
- Earnings per share, before and after dilution amounted to SEK -0.20 (-0.16).

January – September 2021.

- Net sales amounted to TSEK 5,234 (6,310).
- Operating result amounted to TSEK -147,987 (-125,386).
- Earnings before tax amounted to TSEK -173,780 (-127,970).
- Operating cash flow amounted to TSEK -140,138 (-140,260).
- Earnings per share, before and after dilution amounted to SEK -0.40 (-0.48).

Financial overview.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020	Jan-Dec 2019
Net income	1,449	2,470	5,234	6,310	12,286	2,398
Operating result (including associated company result)	-46,829	-40,977	-147,987	-125,386	-230,577	-79,809
Net financial items	-833	4,345	-25,793	-2,584	-13,575	-9,875
Result before tax	-47,662	-36,632	-173,780	-127,970	-244,152	-89,685
Total assets	303,660	384,047	303,660	384,047	338,917	255,664
Equity per share (SEK)	0.63	1.64	0.63	1.64	1.23	1.67
Equity ratio to total assets (%)	81%	87%	81%	87%	74%	81%

For definitions, see note 11.

Comments on the financial results.

Financial results for July–September 2021.

Income.

Net sales were TSEK 1,499 (2,470). Other operating income amounted to TSEK 0 (103) for the period. Capitalized expenditure for development were TSEK 13,387 (11,951).

Operating result.

Operating result for the period amounted to TSEK -46,829 (-40,977). Among the reasons for the weaker result was increased amortization of capitalized development. Depreciation was TSEK -13,946 (-7,470). Brighter contributed TSEK -34,084 to the operating result. The rest refers to Camanio and Nectarine Health™.

Average headcount during the quarter (Full Time Equivalents – FTE) reached 109. The number of FTE being 66 (79,5) employees and 43 (40,5) consultants.

The staff cost amounted to TSEK -16,966 (-18,445) of which TSEK -6,981 relates to Brighter and the rest refers to Camanio and Nectarine Health™.

Other external costs increased and amounted to TSEK -31,084 (-27,697) of which TSEK -16,160 relates to Brighter and the rest refers to Camanio and Nectarine Health™.

Cash flow.

At the start of the quarter, the Group had cash of TSEK 15,620 (23,470), decreasing to TSEK 4,553 (14,399) by the end of period.

Cash flow from operating activities amounted to TSEK -55,595 (-35,361). Investments amounted to TSEK -9,023 (-16,444) of which investment of TSEK -9,023 (-14,551) in intangible assets and TSEK 0 (1,893) in property, plant and equipment.

Financing of TSEK 53,552 (42,735) after costs was raised during the period mainly through the conversion of warrants into shares.

Total cash flow for the period amounted to TSEK -11,067 (-9,070).



Financial results for January–September 2021.

Income.

Net sales were TSEK 5,234 (6,310). Other operating income amounted to TSEK 2,556 (1,142). Capitalized development costs were SEK 42,049 (39,487).

Operating result.

Operating result for the period amounted to TSEK –147,987 (–125,386). Brighter contributed TSEK –113,388 to the operating result and the rest refers to Camanio and Nectarine Health™. This mainly refers to increased amortization of capitalized expenditure for development work in Brighter AB. Depreciation and amortization in total were TSEK –43,882 (–20,680) of which TSEK –39,944 refers to Brighter and the rest refers to Camanio and Nectarine Health™.

Average headcount during the period (Full Time Equivalents – FTE) reached 113. The number of FTE being 75 employees and 38 consultants.

The staff cost amounted to TSEK –54,525 (–51,884) of which TSEK –23,450 relates to Brighter and the rest refers to the operations in Camanio and Nectarine Health™.

Other external costs increased and amounted to TSEK –89,798 (–95,621) of which TSEK –62,752 relates to Brighter and the rest refers to the operations in Camanio and Nectarine Health™.

Financial position.

Capitalized expenditure for development work during the period amounted to TSEK 42,049 (39,487), of which TSEK 15,311 relates to the development in Brighter, TSEK 16,444 relates to Nectarine Health™ and TSEK 10,294 relates to Camanio. Book value of capitalized expenditure totaled TSEK 166,052 (191,198). Patents and trademarks were TSEK 8,210 (7,194). The total intangible assets are TSEK 184,267 (208,005) of which TSEK 94,237 relates to Brighter and the rest to Camanio and Nectarine Health™.

Book value of property, plant and equipment totaled TSEK 25,678 (37,115) of which equipment tools and installations in use TSEK 16,806 (21,111). Also, right-of-use assets relating to the rental agreements and leasing agreement for other assets held by the Group were TSEK 8,872 (16,004).

Financial assets mainly consist of shares of 9,11% ownership in Accumbo AB with a book value of TSEK 11,095.

Inventory amounted to TSEK 23,716 (19,065) of which TSEK 20,813 relates to Brighter and the rest to Camanio.

Other current receivables, TSEK 47,612 (79,784) include pre-payments to Sanmina, for production of Actiste devices of TSEK 42,287 (79,784).

At the end of the period the Group had equity of TSEK 246,769 (335,894), an equity ratio of 81% (87%).

The Group's long-term interest-bearing debt of TSEK 6,293 (9,203) relates mainly to a loan from Almi held by Camanio and the long-term part of leasing liabilities.

Cash flow.

At the beginning of the period, the Group had cash of TSEK 7,276 (9,340) changing to TSEK 4,553 (14,399) by the end of the period.

Cash flow from operating activities after change in working capital amounted to TSEK –140,138 (–140,260).

Investments amounted to TSEK –39,153 (–88,729), of which investment of TSEK –39,161 (–47,926) in intangible assets, and TSEK 0 (–4,838) in property, plant and equipment.

Financing of TSEK 176,569 (234,049) after costs was raised during the period. New issues contributed TSEK 200,856 (244,053).

Total cash flow for the period amounted to TSEK –2,723 (5,060).

Sales.

During this quarter, several important commercial milestones were reached for both Actiste® and for our subsidiaries Camanio and Nectarine Health™. When it comes to Actiste®, we continue focusing on several key markets in the Middle East, Africa, and Southeast Asia. We have ongoing discussions with distributors in the African market regarding the Actiste® Service, and we are continuously working with partners in the United Arab Emirates. We have also received a very welcome preliminary assessment from the UAE's Ministry of Health and Prevention that Brighter's Actiste® device is considered to fall within the "simple device" categorization which means the data storage elements in Brighter's Actiste® Diabetes Management Solution will be exempt from the current data localization requirements in the Health Data Law in the UAE. This will enable Brighter to store and process the data entered from Actiste® Diabetes Management Solution for users and patients who are based in the UAE.

In Indonesia we are working closely with Padjadjaran University to drive a research project where 100 patients with diabetes will use Actiste® Mini for six months to monitor their blood glucose levels. Studies like this are incredibly important, not only for the data they bring but also in terms of

relationship building with academics, medical practitioners, business administrators and key opinion leaders.

In Sweden, Chronos Care has received their first shipment of Actiste® Mini devices and is ready to start the proof-of-concept trials and we are also evaluating the user trials on the west coast. A new commercial collaboration with VivBon has expanded Brighter's sales channels in Sweden where they will sell Brighter's Actiste® and Actiste® Mini portfolio for diabetes management to its customers. VivBon is a Swedish service provider that offers a wide range of personalized services and solutions for seniors and their relatives. This collaboration will help us increase our user base and gain valuable insights and data on user experience.

In addition, Brighter's subsidiary Nectarine Health™, began extending its friendly user trials in the U.S in mid-July, with the aim to receive further feedback on the latest version of Nectarine Health™ at Home and to receive additional data points on "activities of daily living". Users could also continue with the service and buy Nectarine Health™ at Home at a discount. Another essential step towards our commercialization plan in the U.S has been the publishing of price levels for Nectarine Health's™

solution which contributes to our long-term vision to provide an affordable solution that supports ageing at home. About a month later Nectarine Health™ entered into an agreement and expanded the trials with Solutionology Health, a leading reimbursement specialist, to gain market access and insights for the company's artificial intelligence driven home care system for the elderly in the U.S. This will bring additional users to the ongoing friendly user trials in the U.S. to test how the remote care system Nectarine Health™ at Home could work within its business model. This collaboration aims to explore new sales opportunities in the insurance-backed U.S. healthcare market with the potential to provide medical professionals with a way to remotely manage and monitor patients. In late August another important milestone was achieved when Nectarine Health™ was granted two patents by the United States Patent and Trademark Office, relating to the Nectarine Health™ at Home care system.

During the quarter Camanio has also been very active, winning allocation decisions for stationary care alarms with no fewer than three Swedish municipalities; Vansbro Municipality, Österåker Municipality and Borgholm Municipality.



Future liquidity position.

The commercialization of Actiste, development and expansion of the Brighter, Camanio and Nectarine Health™ operations requires that the Group has adequate working capital for inventory, build-up of production as well as continued product development. Funding the business is a very important part of the Group's growth strategy and a continuous part of the work of the Group Leadership. In February 2021 Brighter closed a preferential unit issue raising SEK 142 million.

The upcoming rights issue together with the unit issue TO7 along with the sale or alternative financing of the subsidiaries is expected to fund the business for at least another 12 months.

Furthermore, the Board and Group Leadership are continuously working on and evaluating financing options for the Group to secure the funds and resources needed to pursue the necessary strategy work including financing options such as export financing, contract financing and prepayments from customers.

Risks.

The principal risks and sources of uncertainty for Brighter include financial risks, such as the future earnings trend, financing, liquidity and currency and credit risks. In addition to market and commercialization risks there are risks associated with Brighter's operations, such as dependencies of suppliers and key personnel, obtaining necessary approval from authorities, product development, patents and intellectual property rights and product responsibility. Further information on the Group risk exposure and risk assessment work can be found in Brighter's 2020 Annual Report pages 29–32 and in Note 20.

Shareholders.

On September 30th, 2021, Brighter AB had about 16,610 shareholders, of which the ten largest represented approximately 20,74% of the capital and votes. The total number of shares amounted to 390,311,348 at the end of the period. The table to the right illustrates the ten largest shareholders.

Warrants have been issued on several occasions to employees as incentives and to the shareholders as part of financing solutions. There are currently one listed warrant serie; TO5. For further description and status of all the warrant program please see Note 22 and 25 of Brighter's 2020 Annual Report.

Name	Number of shares	Ownership
1. Försäkringsbolaget Avanza Pension	39 577 608	10,14%
2. Nordnet Pensionsförsäkring	6 828 745	1,75%
3. NA Gruppen AB	6 200 000	1,59%
4. Solokvist AB	5 709 724	1,46%
5. Ålandsbanken in the name of owner	4 669 159	1,20%
6. Swedbank Försäkring AB	4 654 252	1,19%
7. Truls Sjöstedt	4 383 252	1,12%
8. Ålandsbanken AB, W8iMY	4 108 088	1,05%
9. Thore Andre Nordbö	2 666 867	0,68%
10. Försäkringsaktiebolaget Skandia	2 175 605	0,56%



Financial Statements.

Consolidated statement of comprehensive income.

Amounts in TSEK	Note	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Net sales		1,449	2,470	5,234	6,310
Capitalized development costs		13,387	11,951	42,049	39,487
Other operating income		0	103	2,556	1,142
Total operating income		14,836	14,524	49,839	46,939
Raw materials and consumables		703	-1,645	-7,722	-3,460
Other external costs	3	-31,084	-27,697	-89,798	-95,621
Staff costs		-16,966	-18,445	-54,525	-51,884
Depreciation/amortization and write-offs of tangible and intangible assets		-13,946	-7,470	-43,882	-20,680
Other operating costs		-373	-244	-1,898	-680
Operating result		-46,829	-40,977	-147,987	-125,386
Other financial income		-1	4,662	1,731	3,517
Financial expenses	5	-831	-317	-27,523	-6,102
Net financial items		-833	4,345	-25,793	-2,584
Result before income tax		-47,662	-36,632	-173,780	-127,970
Income tax		0	0	0	0
Result for the period		-47,662	-36,632	-173,780	-127,970
Other comprehensive income:					
Translation differences on foreign operations		1,203	-423	1,046	76
Total comprehensive income for the period		-46,459	-37,055	-172,734	-127,894
Attributable to the parent company's shareholders		-46,459	-37,055	-172,734	-127,894
Amounts in TSEK		Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Earnings per share before dilution	4	-0.20	-0.16	-0.40	-0.48
Earnings per share after dilution	4	-0.20	-0.16	-0.40	-0.48

Consolidated statement of financial position.

Amounts in TSEK	Note	Sep 30, 2021	Sep 30, 2020	Dec 31, 2020
Capitalized expenditure for development work		166,052	191,198	162,309
Concessions, patents, licenses, trademarks and similar rights		8,210	7,194	7,396
Goodwill		10,006	9,613	10,007
Total intangible assets		184,267	208,005	179,711
Equipment, tools and installations		16,806	21,111	19,971
Right-of-use assets		8,872	16,004	14,986
Construction in progress		0	0	0
Total property, plant and equipment		25,678	37,115	34,957
Other long-term securities		12,062	9,970	9,969
Other long-term receivables		1,647	1,647	1,647
Total financial assets		13,709	11,617	11,616
Total fixed assets		223,654	256,738	226,284
Inventories		23,716	19,065	9,035
Total Inventories		23,716	19,065	9,035
Accounts receivable	6	803	996	2,524
Current tax assets		1,141	3,437	3,586
Other current receivables		47,612	79,784	79,840
Prepayments and accrued income		2,181	9,628	10,372
Total current receivables		51,737	93,845	96,322
Cash and cash equivalents	6, 7	4,553	14,399	7,276
Total current assets				
TOTAL ASSETS		80,005	127,309	112,633
		303,660	384,047	338,917

Amounts in TSEK	Note	Sep 30, 2021	Sep 30, 2020	Dec 31, 2020
Share capital		19,516	10,865	11,450
Other contributed equity		872,620	682,075	713,205
Retained earnings		-645,366	-357,045	-472,632
Total equity		246,769	335,894	252,023
Total equity attributable to parent company shareholders		246,769	335,894	252,023
Long-term interest-bearing liabilities		6,293	9,203	8,548
Other long-term liabilities		0	63	0
Total long-term liabilities	6, 7	6,293	9,266	8,548
Accounts payable	6	11,633	16,915	27,664
Other interest-bearing debt		23,295	6,956	32,816
Accrued tax liabilities		2,049	0	3,207
Other current liabilities		4,659	6,507	4,160
Accruals and deferred income		8,960	8,508	10,499
Total current liabilities		50,596	38,886	78,346
TOTAL EQUITY AND LIABILITIES		303,660	384,047	338,917

Consolidated statement of changes in equity.

Amounts in TSEK	Share capital	Other contributed equity	Result carried forward (including result for the period)	Total equity
Balance at January 1, 2020	4,806	432,689	-229,720	207,775
Result for the period			-127,970	-127,970
Translation differences on foreign operations			76	76
Total comprehensive income			-127,894	-127,894
Transactions with shareholders				
New issues for cash	5,946	238,107		244,053
New issues for non-cash consideration	113	12,852		12,965
Issue costs		-1,004		-1,004
Total transactions with shareholders	6,059	249,955	0	256,014
Balance at September 30, 2020	10,865	682,644	-357,614	335,895
Balance at January 1, 2021	11,450	713,205	-472,632	252,023
Result for the period			-173,780	-173,780
Translation differences on foreign operations			1,046	1,046
Total comprehensive income			-172,734	-172,734
Transactions with shareholders				
New issues for cash	2,150	42,546	0	44,696
New issues for non-cash consideration	5,916	136,059		141,975
Issue costs		-19,191		-19,191
Total transactions with shareholders	8,065	159,415	0	167,480
Balance at September 30, 2021	19,516	872,620	-645,366	246,769

Consolidated statement of cash flows.

Amounts in TSEK	Note	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Operating result		-46,829	-40,977	-147,987	-125,386
Adjustment for items not included in the cash flow	10	13,337	7,470	43,273	20,680
Interest received		0	0	0	5
Interest paid		-3,011	0	-6,862	-182
Cash flow from operating activities before change in working capital		-36,503	-33,508	-111,576	-104,883
Increase/decrease in inventories		-6,999	-1,843	-14,681	-7,437
Increase/decrease in operating receivables		8,547	-299	24,719	-10,253
Increase/decrease in operating liabilities		-20,641	289	-38,601	-17,686
Total change in working capital		-19,092	-1,853	-28,562	-35,377
Cash flow from operating activities		-55,595	-35,361	-140,138	-140,260
Investments in intangible assets		-9,023	-14,551	-39,161	-47,926
Investments in property, plant and equipment		0	-1,893	0	-4,838
Investments in and loans to associated companies		0	0	0	0
Investment in financial assets		0	0	8	-35,965
Cash flow from investment activities		-9,023	-16,444	-39,153	-88,729
Loans raised/paid		-5,330	0	-5,097	-9,000
New share issues and warrants		58,881	42,735	200,856	244,053
New share issue costs		0	0	-19,191	-1,004
Cash flow from financing activities		53,552	42,735	176,569	234,049
Cash flow for the period		-11,067	-9,070	-2,723	5,060
Opening cash and cash equivalents		15,620	23,470	7,276	9,340
Closing cash and cash equivalents		4,553	14,399	4,553	14,399

Parent company income statement.

Amounts in TSEK	Note	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Net sales		46	1	62	9
Capitalized development costs		5,008	4,885	15,311	20,728
Other operating income		-30	90	960	387
Total operating income		5,024	4,976	16,333	21,123
Other external costs		-15,537	-21,487	-62,212	-71,650
Staff costs		-6,298	-6,511	-20,954	-18,985
Depreciation/amortization of tangible and intangible assets		-12,719	-5,137	-38,155	-15,304
Other operating costs		-68	316	-475	967
Total operating costs		-34,622	-32,820	-121,796	-104,972
Operating result		-29,599	-27,845	-105,464	-83,849
Other interest income and similar income		0	1,548	1,606	3,553
Interest expenses and similar expenses		-8,351	-7,042	-56,617	-15,709
Total result from financial items		-8,351	-5,494	-55,011	-12,156
Result after financial items		-37,950	-33,339	-160,475	-96,005
Appropriations		0	0	0	0
Tax on result for the period		0	0	0	0
Result for the period		-37,950	-33,339	-160,475	-96,005

Parent company balance sheet.

Amounts in TSEK	Note	Sep 30, 2021	Sep 30, 2020	Dec 31, 2020
Capitalized expenditure for development work		86,071	136,221	105,989
Concessions, patents, licenses, trademarks and similar rights		8,165	7,180	7,337
Total intangible assets		94,237	143,401	113,326
Equipment, tools and installations		15,879	19,706	18,712
Total property, plant and equipment		15,879	19,706	18,712
Shares in Group companies		64,226	30,754	70,040
Other long-term securities		12,060	9,959	9,960
Other long-term receivables		1,647	1,647	1,647
Total financial assets		77,933	42,360	81,647
Total fixed assets		188,048	205,467	213,684
Inventories		23,855	13,885	8,895
Total Inventories		23,855	13,885	8,895
Accounts receivable		0	0	0
Receivable on subsidiary		69,191	83,917	32,420
Other receivables		48,253	82,719	83,201
Prepayments and accrued income		1,565	6,775	7,290
Total current receivables		119,009	173,412	122,912
Cash at bank and in hand		2,788	4,263	0,597
Total current assets		145,652	191,560	132,404
TOTAL ASSETS		333,701	397,027	346,088

Amounts in TSEK	Note	Sep 30, 2021	Sep 30, 2020	Dec 31, 2020
Share capital		19,516	10,865	11,450
Development expenses fund		86,071	125,915	105,989
Restricted equity		105,587	136,780	117,439
Share premium		872,621	682,644	713,205
Result carried forward		-517,764	-341,080	-320,979
Result for the period		-160,475	-96,005	-216,703
Unrestricted equity		194,382	245,559	175,523
Total equity		299,969	382,339	292,962
Accounts payable		9,317	8,635	19,388
Other interest-bearing debt		20,400	0	26,250
Other liabilities		1,393	1,061	1,020
Accruals and deferred income		2,622	4,992	6,467
Total current liabilities		33,732	14,689	53,125
TOTAL EQUITY AND LIABILITIES		333,701	397,027	346,088

Notes.

Note 1. Accounting principles.

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report.

Significant accounting and valuation principles are detailed in Note 1 in Brighter's 2020 Annual Report. Important estimates and assumptions for accounting purposes can be found in Brighter's 2020 Annual Report in Note 3.

Note 2. General information.

Brighter AB (publ.) corporate registration number 556736-8591 is a Parent Company registered in Sweden, with its registered office in Stockholm, at Borgarfjordsgatan 18, SE-164 40 Kista, Sweden. The business is located at this address. Brighter develops technical and digital medical devices with a primary area of application in the treatment of diabetes. Brighter AB (publ) has a wholly owned subsidiary, Brighter One AB, the only function of which is to hold warrants as part of the external financing of the Group and as part of the incentive programs. Brighter AB also has a subsidiary in the United Arab Emirates. The name of this government-contract-eligible mainland subsidiary is Brighter Software Trading L.L.C., with management control held by Brighter AB.

From the fourth quarter 2019, Brighter AB has a wholly owned subsidiary in Camanio AB as well as the subsidiary wholly owned by Camanio AB; Bestic AB.

From the first quarter 2020, Brighter AB has a vast majority owned subsidiary in Pink Nectarine Health AB as well as the subsidiaries wholly owned by Pink Nectarine Health AB; Nectarine Health Solutions Limited and Camanio Care Inc (to be name changed). A number of employees own a small number of shares in Pink Nectarine Health AB as part of an incentive plan and the rest is owned by Brighter AB.

Brighter AB is listed on Nasdaq First North Growth Market (BRIG). The Brighter Certified Adviser on Nasdaq First North Growth Market is Eminova Fondkommission AB. Phone: +46 (8) 684 211 00. E-mail: info@eminova.se.

The figures in the report are reported in TSEK unless otherwise stated.

Note 3. Specification of other external costs.

Brighter's other external costs for Jan-Sep 2021 are TSEK 62,752. Nectarine and Camanio make up the rest with TSEK 15,458 to Nectarine and Camanio with TSEK 11,588.

Other external costs mainly consist of consultancy costs, mostly for FTE consultants. An FTE consultant contributes in every way equal to an employee, but receives payment over invoice.

Note 4. Earnings per share.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Result for the period attributable 100% to the Parent Company's shareholders	-37,950	-33,339	-160,475	-96,005
Number of shares at end of period before dilution*	390,311,348	217,291,255	390,311,348	217,291,255
Number of shares at end of period after dilution*	394,323,400	221,303,307	394,323,400	221,303,307
Weighted average number of shares before dilution*	390,311,348	205,121,472	335,357,650	198,684,462
Earnings per share as a weighted average before dilution	-0.20	-0.16	-0.40	-0.48
Earnings per share (SEK) as a weighted average after dilution*	-0.20	-0.16	-0.40	-0.48

*Average number of shares has been recalculated according to IAS 33 for the periods preceding the completed rights issue in 2021.

Note 5. Specification of interest expenses and similar expenses.

Group.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Interest and similar	831	317	4,682	6,102
Write-off of receivable	0	0	22,842	0
Interest expenses and similar expenses	831	317	27,523	6,102

Parent.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Interest and similar	780	7,042	6,428	15,709
Write-off of receivable	0	0	22,842	0
Write-off receivable on subsidiary	7,571	0	27,347	0
Interest expenses and similar expenses	8,351	7,042	56,617	15,709

Note 6. Financial instruments.

Financial Assets.

TSEK	Sep 30 2021	Sep 30 2020	Dec 31, 2020
Financial assets valued at fair value over P & L	12,062	9,970	9,969
Assets at acquisition value			
Accounts receivable	803	996	2,524
Depositions on collaboration and rental agreements	1,647	1,647	1,647
Short term interest-bearing receivable	2,718	35,352	29,573
Cash and equivalents	4,553	14,399	7,276
TOTAL	21,783	62,364	50,989

Financial Liabilities.

TSEK	Sep 30 2021	Sep 30 2020	Dec 31, 2020
Long term interest-bearing debt	6,293	9,266	8,548
Short term interest-bearing debt	23,295	6,956	32,816
Accounts payable	11,633	16,915	27,664
TOTAL	41,221	33,137	69,028

Note 7. Borrowing and net liabilities.

TSEK	Sep 30 2021	Sep 30 2020	Dec 31, 2020
Long term			
Long term interest bearing debt	6,293	9,266	8,548
Short term			
Liabilities relating to interest-bearing debt	23,295	6,956	32,816
Total borrowing	29,588	16,223	41,363
Cash and cash equivalents	4,553	14,399	7,276
Net debt interest-bearing liabilities	25,035	1,823	34,087
Equity	246,769	335,894	252,023
Debt to equity ratio	10,1%	0,5%	13,5%

Note 8. Transactions with affiliated parties.

Transactions with affiliated parties in the form of remuneration, in addition to the Board fee, were carried out with the following Board members. From January 1st to September 30th Christer Trägårdh received SEK 1,200,00 for consultancy services and SEK 24,732 for travel costs as Interim CEO. The amounts are exclusive of VAT. All transactions are carried out on a commercial basis.

Note 9. Segment information.

Brighter's operating segments consist of Brighter, Camanio and Nectarine Health™.

Brighter AB develops mobile solutions in health-tech that facilitates treatment, collects reliable data and enables communication between the patient, relatives and healthcare. Initially, the offer is focused on diabetes.

Camanio AB develops digital solutions for care primarily aimed at the elderly in their home or at retirement homes. The company offers digital service platforms in healthcare, robotics, digital tools and smart technology.

Nectarine Health AB is a Swedish company that develops artificial intelligence solutions within elderly care at home or in nursing homes. The initial offer was, in the form of a bracelet, focused on detecting falls and creating a safe and yet independent life for the elderly person.

Net sales.

There has been a smaller transaction between the segments invoiced at cost of purchases. The revenues from external customers that are reported for the segments to the Group leadership are valued in the same way as in the consolidated income statement.

Segments assets and liabilities.

The segment's assets and liabilities are measured in the same way as in the financial reports. Assets and liabilities are allocated based on the segment's operations.

Note 9 Segment information.

Net Sales from customers per segment.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Segments				
Brighter	1	0	1	8
Camanio	1,138	2,015	4,217	5,286
Nectarine	310	454	1,015	1,258
Elimination	0	0	0	-243
Total Group Net Sales from customers	1,450	2,469	5,234	6,309

Earnings before tax per segment.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Segments				
Brighter	-42,507	-35,637	-166,490	-102,772
Camanio	-3,890	-4,609	-13,381	-14,661
Nectarine	-10,775	-6,587	-23,195	-20,737
Elimination	9,510	10,200	29,286	10,200
Total Group Earnings before tax	-47,662	-36,633	-173,780	-127,970

Assets per segment.

TSEK	Sep 30 2021	Sep 30 2020	Dec 31, 2020
Segments			
Brighter	338,628	391,072	356,038
Camanio	42,693	40,109	39,628
Nectarine	57,024	49,728	44,966
Elimination	-134,686	-96,862	-101,716
Total Assets Group	303,660	384,048	338,917

Liabilities per segment.

TSEK	Sep 30 2021	Sep 30 2020	Dec 31, 2020
Segments			
Brighter	44,034	25,516	63,417
Camanio	26,225	40,031	10,98
Nectarine	56,697	49,458	50,516
Elimination	-70,067	-66,853	-38,02
Total Liabilities Group	56,889	48,152	86,893

Note 10. Specification of items not included in the cash flow.

TSEK	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020
Depreciation/amortization of tangible and intangible assets	13,946	7,470	43,882	20,680
Write-off inventories	0	0		0
Capital gain/loss on assets		0		0
Currency gain/loss	-609	0	-609	0
Cash flow from operating activities before change in working capital	13,337	7,470	43,273	20,680

Note 11. Financial key figures.

Definition of key figures.

Net sales	Sales to external customers
Operating profit/loss	Profit/loss before financial items
Profit/loss for the period	Profit/loss after financial items
Earnings per share	Shareholders' equity via the number of outstanding shares before dilution
Operating margin %	Total income via operating profit/loss
Equity ratio %	Shareholders' equity via balance sheet total
Debt to equity ratio	Interest-bearing liabilities in relation to shareholders' equity
Net debt	Interest-bearing liabilities less interest-bearing assets and cash and cash equivalents
Working capital	All current assets minus current liabilities
Net financial items	Financial income minus financial costs
Balance sheet total	Total assets on balance sheet
Other external costs	All costs included in operating profit/loss, except for costs of goods sold, personnel costs and depreciation and share of earnings from associated companies.

Significant events after the end of the quarter.

- Brighter's board has decided to prioritize sale over alternative financing regarding the subsidiaries Camanio and Nectarine Health™ and its ownership in Accumbo.
- Brighter signs a reseller agreement for Actiste® Mini with Medico in Indonesia.
- Change in Brighter's Board – Emilie Erhardh Winiarski resigns as a board member.
- Brighter's subsidiary Camanio wins allocation decision with Ragunda and Strömsunds Municipalities for stationary care alarms.
- The subscription period for Brighter's warrant T06 expired on November 1, 2021, in accordance with the applicable terms.
- The Board decided to carry out an issue of units consisting of shares and warrants with preferential rights for existing shareholders of approximately SEK 117 million, which is subject to the shareholders' subsequent approval on the extraordinary general meeting on December 7.

Financial calendar.

Full year and Interim Report Q4 2021	28 February 2022
Interim Report Q1 2022	4 May 2022
Interim Report Q2 2022	10 August 2022
Interim Report Q3 2022	9 November 2022

Submission of interim report.

Stockholm, November 14, 2021.
Brighter AB (publ).

The Board of Directors and the CEO certify that the interim report for the period provides a fair view of the operations, financial position and results of the Parent Company and the Group, and describes material risks and uncertainties facing the Parent Company and the companies included in the Group.

Christer Trägårdh
Chairman of the Board

Habib Al Assaad
Board Member

Åsa Sjöblom Nordgren
Board Member

Clas Lindbergson
Board Member

Karin O'Connor
Board Member

Erik Lissner
Interim CEO

Review by the auditor.

This interim report has not been reviewed by the company's auditor.

About Brighter.

Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, Brighter's aim is to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Besides the wholly owned and controlled subsidiaries Camanio and Nectarine Health™, Brighter has made a strategic investment in digital care provider Accumbo.

Proactive and data driven medical care.

Brighter has developed unique solutions and services based on patented technology that aim to facilitate more proactive, efficient and data driven medical care, primarily with regard to diabetes under the "Actiste" brand family. The solutions are based on a concept that Brighter refers to as "The Benefit Loop" – a personal, holistic and data centered approach to medical care. The Company has also made a strategic investment in Swedish digital care provider Accumbo, which focuses on hypertension (high blood pressure). Accumbo has successfully launched the Blodtrycksdoktorn [Blood Pressure Doctor] service in Sweden.

Digital care and support in the home.

During 2019 and 2020, Brighter expanded into the "age-tech" and care sector through the acquisitions of Camanio and Nectarine Health™, focusing on innovative technology and services for care and support in the home. Brighter's subsidiary Camanio has a broad product portfolio comprising both digital services and physical products enabling a smooth transition to digital care at home. Brighter's other subsidiary, Nectarine Health™, has developed a remote monitoring solution using AI technology to give seniors the confidence to live independently at home for longer, without having to compromise their privacy or dignity, feeling safe and secure knowing that if they experience a health issue, help is always near.



For further information, please contact:

Erik Lissner, Interim CEO

Phone: +46 72 999 38 60

E-mail: erik.lissner@brighter.se

Christopher Robinson, Interim CFO

Phone: +46 70 777 40 14

E-mail: christopher.robinson@brighter.se



Brighter AB (publ) 556736-8591. +46 (0)8-550 088 20

Borgarfjordsgatan 18
164 40 Kista

www.brighter.se

info@brighter.se

Investor relations:
ir@brighter.se

Brighter